5'-Dimethylamino-5'-desoxyadenosin | 78694-79-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 5'-Dimethylamino-5'-desoxyadenosin
• 英文别名: 5'-deoxy-5'-(N,N'-dimethylamino)adenosine；5'-dimethylamino-5'-deoxy-adenosine；5'-Deoxy-5'-(Dimethylamino)adenosine；(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
• CAS: 78694-79-8
• 化学式: C₁₂H₁₈N₆O₃
• 分子量: 294.313
• InChiKey: SLNWRDWGFHZRAQ-WOUKDFQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  磷酸三甲酯 、 5'-Dimethylamino-5'-desoxyadenosin 以72%的产率得到5'-Trimethylammonio-5'-desoxyadenosin
  参考文献：
  名称：

  Morr, Michael; Ernst, Ludger, Journal of Chemical Research, Miniprint, 1981, # 4, p. 1153 - 1177

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 5-氨基腺苷酸 在 sodium tetrahydroborate 作用下， 以65%的产率得到5'-Dimethylamino-5'-desoxyadenosin
  参考文献：
  名称：

  Morr, Michael; Ernst, Ludger, Journal of Chemical Research, Miniprint, 1981, # 4, p. 1153 - 1177

  摘要：

  DOI：

文献信息

• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。
• 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase
  申请人：Secrist, III John A.

  公开号：US08637485B2

  公开（公告）日：2014-01-28

  The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5′-deoxy-5′-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5′-deoxy-5′-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.

  S-腺苷甲硫氨酸甲酯与hΛdoMetDC F223A复合物的晶体结构，其中F7，腺嘌呤和F223的芳香环堆叠被消除。该突变体与酯的结构表明，配体仍然通过与F7的pi-pi相互作用，与Glu67的背骨氢键和静电相互作用维持同步构象。合成了几系列具有不同取代基的腺嘌呤8位的AdoMet底物类似物，并分析了它们抑制hAdoMetDC的能力。为了理解这些结果，实验确定了酶抑制剂复合物和人类AdoMetDC与5'-去氧-5'-[N-甲基-N-[2-(氨氧)乙基]氨基-8-甲基]腺苷（MAOEMA）和5'-去氧-5'-[N-甲基-N-[4-(氨氧)丁基]氨基-8-乙基]腺苷（MAOBEA）在活性位点的晶体结构。
• 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE
  申请人：Secrist, III John A.

  公开号：US20110009354A1

  公开（公告）日：2011-01-13

  The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5′-deoxy-5′-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5′-deoxy-5′-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.

  S-腺苷甲硫氨酸甲酯与hΛdoMetDC F223A复合物的晶体结构已被确定，该突变体中F7、腺嘌呤和F223的芳香环堆叠被消除。该突变体与酯的结构表明，配体仍通过与F7的π-π相互作用、与Glu67骨架的氢键和静电相互作用来维持同构构象。合成了几个AdoMet底物类似物系列，这些类似物在腺嘌呤的8位具有不同的取代基，分析它们抑制hAdoMetDC的能力。为了理解这些结果，通过虚拟建模酶抑制剂复合物和人类AdoMetDC与5'-去氧-5'-[N-甲基-N-[2-(氨氧)乙基]氨基-8-甲基]腺苷(MAOEMA)和5'-去氧-5'-[N-甲基-N-[4-(氨氧)丁基]氨基-8-乙基]腺苷(MAOBEA)在活性位点的晶体结构已被实验确定。
• 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase.
  申请人：Southern Research Institute

  公开号：EP2574616A2

  公开（公告）日：2013-04-03

  The crystal structure of the complex of S-adenosylmethionine methyl ester with hAdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5'-deoxy-5'-[N-methyl-N-[2-(aminooxy)ethyl]ainino-8-methyl]adenosine (MAOEMA) and 5'-deoxy-5'-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.

  S- 腺苷蛋氨酸甲酯与 hAdoMetDC F223A 复合物的晶体结构，F223A 是一种突变体，在这种突变体中，F7、腺嘌呤和 F223 的芳香环堆积将被消除。这种带有酯的突变体的结构显示，配体仍然通过与 F7 的 pi-pi 相互作用、与 Glu67 骨架的氢键以及静电作用保持合成构象。我们合成了几个系列的 AdoMet 底物类似物，它们在腺嘌呤的 8 位上有多种取代基，并分析了它们抑制 hAdoMetDC 的能力。为了理解这些结果，实验测定了酶抑制剂复合物的虚拟模型以及人 AdoMetDC 与 5'-脱氧-5'-[N-甲基-N-[2-（氨基氧）乙基]氨基-8-甲基]腺苷（MAOEMA）和 5'-脱氧-5'-[N-甲基-N-[4-（氨基氧）丁基]氨基-8-乙基]腺苷（MAOBEA）在活性位点的晶体结构。
• New Insights into the Design of Inhibitors of Human <i>S</i>-Adenosylmethionine Decarboxylase: Studies of Adenine C⁸ Substitution in Structural Analogues of <i>S</i>-Adenosylmethionine
  作者：Diane E. McCloskey、Shridhar Bale、John A. Secrist、Anita Tiwari、Thomas H. Moss、Jacob Valiyaveettil、Wesley H. Brooks、Wayne C. Guida、Anthony E. Pegg、Steven E. Ealick

  DOI：10.1021/jm801126a

  日期：2009.3.12

  S-adenosylmethionine decarboxylase (AdoMetDC) is a critical enzyme in the polyamine biosynthetic pathway and depends on a pyruvoyl group for the decarboxylation process. The crystal structures of the enzyme with various inhibitors at the active site have shown that the adenine base of the ligands adopts an unusual syn conformation when bound to the enzyme. To determine whether compounds that favor the syn conformation in solution would be more potent AdoMetDC inhibitors, several series of AdoMet substrate analogues with a variety of substituents at the 8-position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. The biochemical analysis indicated that an 8-methyl substituent resulted in more potent inhibitors, yet most other 8-substitutions provided no benefit over the parent compound. To understand these results, we used computational modeling and X-ray crystallography to study C(8)-substituted adenine analogues bound in the active site.